AAAAAA
Results: 26-48/48
Authors:
De Francesco, R
Pessi, A
Steinkuhler, C
Citation: R. De Francesco et al., The hepatitis C virus NS3 proteinase: structure and function of a zinc-containing serine proteinase, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 235-245
Authors:
Love, RA
Parge, HE
Wickersham, JA
Hostomsky, Z
Habuka, N
Moomaw, EW
Adachi, T
Margosiak, S
Dagostino, E
Hostomska, Z
Citation: Ra. Love et al., Conformational changes in hepatitis C virus NS3 proteinase during NS4A complexation: correlation with enhanced cleavage and implications for inhibitor design, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 247-254
Authors:
Kato, N
Lan, KH
Ono-Nita, SK
Yoshida, H
Shiratori, Y
Omata, M
Citation: N. Kato et al., Hepatitis C virus non-structural region 5A protein is a potent transcriptional activator, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 255-262
Authors:
Satoh, S
Hirota, M
Inudoh, M
Kato, N
Hijikata, M
Shimotohno, K
Citation: S. Satoh et al., Protein processing of hepatitis C virus and investigation of the effects of viral proteins on cell proliferation, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 263-269
Authors:
Furman, PA
Schinazi, RF
Citation: Pa. Furman et Rf. Schinazi, The mechanism of action and cellular pharmacology of anti-hepatitis B virus agents, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 273-283
Authors:
Lee, JY
Colledge, D
Locarnini, S
Citation: Jy. Lee et al., Pathogenic effects of antiviral therapy in chronic hepatitis B virus infection, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 285-302
Authors:
Chu, CK
Boudinot, FD
Peek, SF
Hong, JH
Choi, Y
Korba, BE
Gerin, JL
Cote, PJ
Tennant, BC
Cheng, YC
Citation: Ck. Chu et al., Preclinical investigation of L-FMAU as an anti-hepatitis B virus agent, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 303-312
Authors:
Perigaud, C
Gosselin, G
Imbach, JL
Citation: C. Perigaud et al., A rational strategy for the design of anti-hepatitis B virus nucleotide derivatives, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 313-319
Authors:
Cretton-Scott, E
Sommadossi, JP
Citation: E. Cretton-scott et Jp. Sommadossi, Cellular pharmacology of lamivudine in hepatocyte lamivudine in hepatocyteprimary cultures, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 321-325
Authors:
Ono-Nita, SK
Kato, N
Shiratori, Y
Lan, KH
Yoshida, H
Carrilho, FJ
Omata, M
Citation: Sk. Ono-nita et al., Influence of reverse transcriptase YMDD motif variants on replication and lamivudine resistance of hepatitis B virus, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 329-333
Authors:
Burroughs, NJ
Rand, DA
Pillay, D
Elias, E
Mutimer, D
Citation: Nj. Burroughs et al., The consequences of quasispecies heterogeneity and within-host ecology forantiviral therapy of hepatitis B virus, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 335-343
Authors:
Thomas, HC
Citation: Hc. Thomas, Mathematical modelling of chronic hepatitis B and C virus infection: a basis for planning new approaches to therapy, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 347-352
Authors:
Wong, WWS
Tyrrell, DLJ
Citation: Wws. Wong et Dlj. Tyrrell, Treatment of hepatitis B virus with lamivudine, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 353-363
Authors:
Trepo, C
Zoulim, F
Citation: C. Trepo et F. Zoulim, Treatment of chronic hepatitis B with famciclovir, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 365-370
Authors:
Poynard, T
Moussali, J
Thevenot, T
Ratziu, V
Opolon, P
Citation: T. Poynard et al., Treatment of chronic hepatitis C with interferon: 1998 update, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 371-378
Authors:
Sherman, KE
Sherman, SN
Citation: Ke. Sherman et Sn. Sherman, Interferon plus thymosin alpha-1 treatment of chronic hepatitis C infection: a meta-analysis, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 379-383
Authors:
Ascione, A
Canestrini, C
Astretto, S
De Luca, M
Lanza, AG
Morisco, F
Tuccillo, C
Caporaso, N
Froio, F
Piergrossi, P
D'Asero, C
Citation: A. Ascione et al., Primary response to interferon alpha plus ribavirin in non-responders and relapsers with chronic liver disease owing to hepatitis C virus, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 385-386
Authors:
Berenguer, M
Wright, TL
Citation: M. Berenguer et Tl. Wright, Hepatitis C virus in the transplant setting, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 389-402
Authors:
Kruger, M
Manns, MP
Citation: M. Kruger et Mp. Manns, Liver transplantation and hepatitis B: prophylaxis and treatment of re-infection with new antiviral agents, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 403-412
Authors:
Cooper, DA
Citation: Da. Cooper, Effect of lamivudine on hepatitis B virus-human immunodeficiency virus coinfected patients from the CAESAR study, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 415-416
Authors:
Pontisso, P
Gerotto, M
Benvegnu, L
Chemello, L
Alberti, A
Citation: P. Pontisso et al., Coinfection with hepatitis B and C viruses, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 417-422
Authors:
Iino, S
Citation: S. Iino, Relationship between infection with hepatitis C virus and hepatocellular carcinoma in Japan, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 425-429
Authors:
Blumberg, BS
Citation: Bs. Blumberg, Factors influencing the course of hepatitis B virus infection, THERAPIES FOR VIRAL HEPATITIS, 1998, pp. 431-434